Shannon James Samuel 4

What Happened

• Shannon James Samuel, a director of Xilio Therapeutics, reported an open-market purchase of 5,000 shares on March 26, 2026. The filing shows a weighted-average price of $8.79 per share, totaling approximately $43,950. This transaction is classified as a purchase (P), which is generally seen as a direct buy of company stock.

Key Details

• Transaction date: 2026-03-26; Form 4 filed: 2026-03-30 (filed on time).
• Reported price: weighted average $8.79 per share; footnote indicates underlying trades executed in a range of $8.6758 to $9.2499.
• Total shares acquired: 5,000; total value ≈ $43,950.
• Shares owned after transaction: not specified in the provided summary of the filing.
• Footnotes: F1 notes the Column 4 price is a weighted average and that the reporting person can provide details of the number of shares at each price on request. F2 notes reported share counts reflect the 1-for-14 reverse stock split effective March 13, 2026.
• Timeliness: Filing appears timely (filed within required reporting window).

Context

• This was a direct open-market purchase (code P). Purchases by officers or directors represent they acquired shares outright; they do not by themselves explain motivation. The weighted-average price and the footnote suggest the 5,000-share purchase was executed in multiple trades.